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Abstract
Synthetic water-soluble porphyrins and their metalloporphyrin derivatives with Co(Ill), Cu(ll), Ru(ll)
and Pt(ll), containing various functional groups within the meso-positions of the porphyrin, were
synthesised and evaluated as hypoxic agents, especially as cytotoxins and radiosensitisers. Cobalt
complexes of the porphyrins containing positively charged methylpyridinium groups showed
selective toxicity toward hypoxic Chinese Hamster Ovary (CHO) cells. The Co(Ill) complexes of the
cationic and the anionic porphyrins are all weak radiosensitisers toward hypoxic cells, the highest
sensitisation enhancement ratio (SER 1.22, at 50 #M) being with a porphyrin complex containing a
cis-arrangement of two nitro and two methylpyridinium meso-substituents. A copper complex of a
tetracationic porphyrin showed slight radiosensitisation activity with an SER value of about 1.1. The
other metalloporphyrins showed no hypoxic selectivity or radiosensitisation activity. In total, over 50
porphyrin free bases have been synthesised, of which half are water-soluble and have been
metallated; thus, the chemistry is now in place for further development of water-soluble hypoxic
agents.
Introduction
Synthetic, water-soluble porphyrins have been reported to accumulate in tumour tissue [1] and
such compounds containing methylpyridinium, sulfonato or carboxylato substituents, and their
metal complexes, have been reported to be effective radiosensitisers [2]. The potential use of
synthetic porphyrins as hypoxia selective radiosensitisers may overcome a limitation of radiotherapy
which is the lack of selectivity toward tumour cells, especially toward hypoxic tumour cells.
Appropriate porphyrins also have the potential for other aspects of cancer treatments, including
photodynamic therapy [3], chemotherapy [4,5], boron neutron capture [6], and magnetic
resonance imaging [7].
We have initiated a program to design porphyrins [8,9] containing functional groups within meso
-phenyl or pyridyl substituents (positions 5,10,15,and 20, see Figure 1). It has been reported that
nitro groups play a key role for the hypoxic toxicity and radiosensitising activities of nitro-aromatic
compounds such as nitroimidazoles, due to their electron affinities [10]. We have introduced the
nitro (NO2) group, the nitroso group (-NO) into the porphyrin structures in order to increase the
electron affinities, and the positively charged methylpyridinium group to improve solubility
properties of the resultant compounds with the expectation that this may lead to better hypoxia
selective and radiosensitising agents. Finally, considerable interest in nitroaromatics for detection
and quantitation of hypoxia [11] leads us also to explore the use of porphyrins with an antigenic
"tag" similar to that developed by Lord et al. [11], as it has been shown that the antibodies they have
developed can recognize related compounds [12].
Other substituents are also under consideration for improved behaviours of porphyrins with regard
to antitumour activities; for example, -NH2 and pyridyl substituents might be beneficial for the
interaction with DNA because these groups have the potential for hydrogen-bond formation with
the DNA bases. The meso-phenyl and -pyridyl substituents can also be further functionalized to
give water-solubility by sulfonation or N-methylation, respectively [8]. The positively charged
methylpyridinium group may also facilitate interaction with the negatively charged DNA molecules
and cell membranes. The structures of some of the porphyrins synthesised in this program are
shown in Figure 1.Vol. 3, No. 2, 1996 Porphyrins andMetalloporphyrins
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Tet(MPy)P 5,10,15,20-tetrakis(4-methylpyridinium)porphyrin
T(MPy)PhP 5,10,15-tris(4-methylpyridinium)-20-(4-phenyl)porphyrin
T(MPy)(NPh)P 5,10,15-tris(4-methylpyridinium)-20-(4-nitrophenyl)porphyrin
cis-B(MPy)B(NPh)P 5,10-bis(4-methylpyridinium)-I 5,20-bis(4-nitrophenyl)porphyrin
trans-B(MPy)B(NPh)P 5,15-bis(4-methylpyridinium)-10,20-bis(4-nitrophenyl)porphyrin
Tet(SPh)P 5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrin
PyT(SPh)P 5-(4-pyridyl)-I 0,15,20-tris(4-sulfonatophenyl)porphyrin
(APh)T(SPh)P = 5-(4-aminophenyl)-10,15,20-tris(4-sulfonatophenyl)porphyrin
cis-(NPh)PyB(SPh)P=5-(4-n itrophenyl)-10-(4-pyridyl)-15,20-bis(4-suIfonatophenyl)porphy rin
Figure 1. Examples of water-soluble porphyrin free-bases. [APh 4-aminophenyl, MPy= 4-
methylpyridinium, NPh 4-nitrophenyl, P porphyrin, Py 4-pyridyl, SPh 4-sulfonatophenyl;
B=bis, T= tris, Tet tetrakis]. Formation of a metalloporphyrin requires loss of the two pyrrole-N
protons; formulations such as Pt-1 imply that 1 is now the dianion of the free-base porphyrin.
The additional advantages of metal compounds as radiosensitisers and cytotoxins have been
previously summarised [13,14]. In terms of synthesising metalloporphyrins, we have included Pt
and Ru drivatives because complexes of these metals are the most widely recognized for
antitumour activity with mechanisms that require binding of the metal to DNA [14]. We have also
included Co and Cu derivatives because complexes of these metals with other porphyrin ligands
have been reported to yield better radiosensitisation properties than corresponding complexes with
other metals [2]. This paper, as a continuation of our earlier reports [8,9], describes in vitro data for
these metalloporphyrins with respect to accumulation in cells, cytotoxicity, radiosensitisation, and
DNA binding properties.
Materials and Methods
Synthesis and Characterisation
The water-soluble porphyrins were synthesised via our recently reported methods [8,9]. The
cationic porphyrins 4 and 5 were isolated as dichloride salts, 2 and 3 as trichlorides and 1 as a
tetrachloride salt. Of the anionic porphyrins, 6 was isolated as a tetrasodium salt, 7 and 8 as
trisodium salts, and 9 as a disodium salt. These salts were used for syntheses of the
metalloporphyrins.
Metallations of the porphyrins were effected using as precursors cis-Pt(H20)2(DMSO)22+,
Ru(DMF)63+, or simple salts of the second row metals Co(ll) and Cu(ll). The Co(.lll complexes of-the
cationic porphyrins 1- 4 were isolated as chloride salts, while those of the anionic porphyrins 6-9
were isolated as sodium salts. The Cu(ll) complexes of 1-3 were isolated as chloride salts; those of
the anionic porphyrins 6-8 were isolated as sodium salts. The Co(Ill) species in aqueous solution
were shown to be six-coordinate with two axial aquo ligands; the Cu(ll) complexes were isolated as
four-coordinate species [15]. The four-coordinate Pt(ll) complexes of 1, and 3-5 were first isolated
as hexafluorophosphates, and the tetracationic and tricationic species (Pt-1 and Pt-3) were then
converted in aqueous solution to the chloride salts [16]. The other two hexafluorophosphates (Pt-4
and Pt-5) were not soluble enough in water for the conversion, and were thus not tested in in vitro
studies. The Ru(ll) complexes of porphyrin 6 were isolated as Na4[Ru(6)(CO)DMF and
Naa[Ru(6)(DMSO)2 [17]. The metalloporphyrins were characterised by elemental analysis, and
UVTis-, mass-, IR-, and 1H- and 195pt-NMR spectroscopies; the details of the inorganic chemistry will
be reported elsewhere.
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Accumulation, Toxicity, Radiosensitisation and DNA Binding Assays
Accumulations of the metalloporphyrins by Chinese hamster ovary (CHO) cells were determined by
atomic absorption spectroscopy for detection of the metal content in the cells [18,19].
Toxicities toward the CHO cells in oxic or hypoxic conditions were performed by incubating a cell
suspension in (z-medium containing the dissolved metalloporphyrin drug; the cells then were
washed and plated for development of colonies (7 days) as described elsewhere [8,19]. Each
experiment was repeated three times and the average results are reported.
For radiosensitisation tests, the CHO cells were incubated for h with medium containing a
dissolved drug, and then cooled to 0C before irradiation using an X-ray source; after irradiation, the
cells were washed free of drug and plated for development of colonies as described previously
[8,19]. Plating efficiency was calculated by dividing the number of colonies by the number of cells
plated (again in triplicate).
Metalloporphyrins were tested for binding to DNA by means of aoplasmid binding assay [20]; DNA
adducts were also tested for recognition by HMG (high mobile group) proteins [21].
Results and Discussion
Accumulation
Significant amounts of Pt accumUlated in the CHO cells after the cells were incubated with the Pt-1
or Pt-3 complexes at 100 #M under air or nitrogen; after 6 h incubation, both complexes showed
about 50% favoured accumulation in hypoxic cells, with the Pt contents reaching 230 and 480
ng/(106 cell) under nitrogen for Pt-1 and Pt-3, respectively. The favoured accumulation of Pt-3 over
Pt-1 presumably results from its lower charge (+3 vs. +4), perhaps because such a species more
readily traverses the hydrophobic interior of the cell membrane. A similar but more pronounced
effect of the charge on cell accumulation has been reported previously for the free-base porphyrins
1 and 3 [8]. The anionic Ru(6)(CO)(DMF) complex accumulates in CHO cells but to a level an order
of magnitude lower than the cationic Pt species [e.g., 6 ng/(106 cell) under corresponding
conditions]; nev.ertheless, the value is comparable to that found for cisplatin [19]. Decreased
accumulation for anionic species (vs. cationic ones) is consistent with the fact that cell membranes
are negatively charged.
Toxicity
The toxicities of the aqueous buffer-soluble Co(Ill) and Cu(ll) complexes of 1-3 and 6-8, the Ru(ll)
complexes of 6, and the Pt(ll) complexes of 1 and 3, were all tested with CHO cells at 100 #M for 1-
3 h incubation at 37C under hypoxic or oxic conditions. The three cationic Co(Ill) complexes of 1-3
showed similar selective toxicities to the hypoxic cells, while being essentially non-toxic toward oxic
cells; the survival of the hypoxic cells incubated with these compounds for 3 h was about 40%
(compared with 85-90% for controls, and aerobic treament). A representative graph of the survival
curves is shown in Figure 2. Other metalloporphyrins were non-toxic under oxic or hypoxic
conditions. The cationic Co(Ill) porphyrins almost certainly have higher reduction potentials than the
other tested metalloporphyrins, and the data would then be consistent with the correlation between
reduction potentials and toxicity established for a series of nitroimidazoles [10]. The mechanism for
the hypoxic selectivity of cobalt(Ill) complexes of aliphatic mustards is considered to involve
reduction of the substitution-inert Co(Ill) complexes to the kinetically labile Co(ll) complexes, and
then release of the toxic mustard ligands [22]. A different mechanism must be involved for the
cationic Co(Ill) porphyrin complexes, because Co(ll) metalloporphyrins are not readily de-metallated
and, in any case, the porphyrin ligands are not toxic [8]. Unfortunately, the selective toxicities are
insufficient for potential clinical use Disappointingly, no increased selectivity was seen for the NO2-
containing complexes (or within th’e free-base porphyrins [8]), while nitroimidazoles are known t-o
show much higher selectivities than imidazole. A Co(Ill) complex of 1 at 100 #M and 1 h incubation
has been reported to be slightly toxic (50% survival) in Chinese hamster fibroblast (V79N) cells
under oxic conditions [2]; at these conditions, we found essentially no toxicity of this complex
toward CHO cells.
Radiosensitisation
The Co(Ill) complexes of 1-3 and 6-8, the Cu(ll) complex of 1, the Pt(ll) complexes of 1 and 3 and
the Ru(II)(6)(DMSO)2 complex were tested as radiosensitisers at 100 #M under hypoxic conditions
in o-medium with or without serum. The less soluble Co(Ill) complexes of porphyrins 4 and 9 were
tested at 50 u.M concentration. The values of the sensitisation enhancement ratio, SER (radiation
dose without drug/radiation dose with drug), were calculated at 1% survival. In contrast to the
porphyrin free-bases which showed SER values of 0.92-1.04 [8], the Co(Ill) and Cu(ll) complexes
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show weak radiosensitiser behaviour with SER values of 1.08-1.22 in a medium containing no
serum, and 1.05-1.15 in a serum-containing medium. The cationic Co(Ill) complexes showed higher
SER values than the anionic Co(Ill) complexes, and the highest value (1.22) was obtained from the
Co(111)-4 species, which contains two methylpyridinium and two nitrophenyl groups (see Figure 2).
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Figure 2. Surviving Fraction curves for radiosensitisation by Co-4;
hypoxic conditions in ( medium without serum, SER 1.22 at 1% survival.
Although the SER value is not of interest for clinical use, the findings suggest that the introduction
of nitro and/or positively charged substituents should increase radiosensitisation activities of
metalloporphyrins, at least for Co(Ill) species. The Cu(ll) complex showed SER values of 1.08 and
1.14 in a medium with or without serum, respectively. The Pt(ll) and Ru(ll) complexes, like the
porphyrin free-bases [8], show no radiosensitisation activity (SER 0.90-1.0). Serum has been
reported to reduce cellular accumulation of Photofrin II (hematoporphyrin derivatives) [23], and thus
may be a factor contributing to the somewhat lower SEFI values obtained in the serum-containing
medium. Cobalt (111) complexes of 1 and 6, and a copper (11) complex of 1, were reported to be
effective radiosensitisers for Chinese hamster fibroblast (V79N) cells, with SER values up to 2.4 [2].
The differences from our findings may result from differences in experimental conditions, cell lines,
monolayers versus suspension, and medium (salt vs (). The characterisation, including purity level,
of the complexes was not reported in the earlier work, and differences in the nature of the
complexes used could also be important. In both studies, the free-base porphyrins 1 and 6 are
ineffective as radiosensitisers [2,8].
DNA Binding
Both Ru(ll) complexes of 6 do bind to DNA (at BamH1, but not EcoR1, binding sites) but are much
less effective inhibitors than cisplatin for DNA damage repair; the interaction of the Ru complexes
with DNA was not recognised by an HMG protein (unlike cisplatin [21,24], and cis-and trans-
RuCI2(DMSO)4 [25]. The detailed mechanisms for these interactions remain to be substantiated.
In conclusion, of a range of water-soluble metalloporphyrin species, Co(Ill) complexes of some
cationic methylpyridinium-substituted porphyrins (sometimes containing also nitrophenyl
substituents) exhibit some selective toxicity and radiosensitising activity toward CHO cells.
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